

**Date:** March 20, 2025

To,  
Sr. General Manager  
Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400001

**BSE Scrip Code: 544319**

To,  
Sr. General Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**NSE Symbol: SENORES**

Dear Sir/Madam,

**Subject: Intimation under Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) -Investment through Rights Issue in Senores Pharmaceuticals Inc., Wholly Owned Subsidiary of the Company**

In furtherance of the objects of the Initial Public Offer (“IPO”), as per the Prospectus of the Company dated December 24, 2024 and pursuant to Regulation 30(6) read with Schedule III Part A Para A(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform that the Company has made a further investment in Senores Pharmaceuticals Inc. (“SPI”), a wholly-owned subsidiary of the Company, through a rights issue.

We have enclosed herewith the details required under Regulation 30 read with Para A (1) of Part A of Schedule III of the Listing Regulations and the SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 as **Annexure -1**.

We request you to take the above information on record.

Thank you.

**For Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**  
Company Secretary and Compliance Officer  
ICSI Membership No.: F11464

Encl.: As above

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)  
W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: U24290GJ2017PLC100263

**Disclosure under Regulation 30(6) read with Para A (1) of Part A of Schedule III of the Listing Regulations and the SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

Sr. No.	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Senores Pharmaceuticals Inc. (“SPI”) is a US based company holding the intellectual properties used by the Company, specifically for its ANDA approvals and enters into agreement with the marketing partners of the Company.  The turnover of SPI for the financial year ended March 31, 2024 was USD 5,938,166.00.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?  If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	SPI, being a wholly owned subsidiary is a related party of the Company. The transaction falls within the ambit of related party transactions and is at arms’ length.  Except to the extent of shares held by the Company in SPI, the Company has no interest in SPI.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This investment is a part of utilization of the issue proceeds as specified in Prospectus dated December 24, 2024 for working capital requirements of SPI.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Requisite approvals under Foreign Exchange Management Act, 1999 have been obtained.
6.	Indicative time period for completion of the acquisition	Not applicable
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	Investment of USD 468,640 (40,400 equity shares of USD 11.60 each on rights basis).
9.	Percentage of shareholding/ control acquired and/or number of shares acquired	There will be no change in the percentage of shareholding of the Company in SPI. It will continue to remain a wholly owned subsidiary of the Company.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity	SPI was incorporated on January 28, 2021 as a wholly owned subsidiary of the Company. SPI is a US based company holding the intellectual properties used by the Company, specifically for

**Senores Pharmaceuticals Limited**

 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

 W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: U24290GJ2017PLC100263

Sr. No.	Particulars	Description						
	has presence and any other significant information (in brief)	<p>its ANDA approvals and enters into agreement with the marketing partners of the Company.</p> <p>The turnover of SPI for last 3 years is given below:</p> <p style="text-align: right;">(Amount in USD)</p> <table border="1" data-bbox="857 449 1412 562"> <thead> <tr> <th data-bbox="857 449 1036 501">Mar-22</th> <th data-bbox="1036 449 1224 501">Mar-23</th> <th data-bbox="1224 449 1412 501">Mar-24</th> </tr> </thead> <tbody> <tr> <td data-bbox="857 501 1036 562">118,240.00</td> <td data-bbox="1036 501 1224 562">3,353,196.00</td> <td data-bbox="1224 501 1412 562">5,938,166.00</td> </tr> </tbody> </table> <p>Country of presence: United States of America</p>	Mar-22	Mar-23	Mar-24	118,240.00	3,353,196.00	5,938,166.00
Mar-22	Mar-23	Mar-24						
118,240.00	3,353,196.00	5,938,166.00						

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)  
 W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: U24290GJ2017PLC100263